CDK4 and breast cancer: Thus, we evaluated the clinical relevance of the combined score of these three proteins in BC samples of a cohort of patients receiving AI-monotherapy (N = 54) and in a cohort of patients treated with combined CDK4/6i and ET (N = 83), both in the advanced setting.